Jacobs I - Search Results

1

Bevacizumab biosimilars: scientific justification for extrapolation of indications.

Melosky B, Reardon DA, Nixon AB, Subramanian J, Bair AH, Jacobs I. Melosky B, et al. Among authors: jacobs i. Future Oncol. 2018 Oct;14(24):2507-2520. doi: 10.2217/fon-2018-0051. Epub 2018 Apr 25. Future Oncol. 2018. PMID: 29690784 Free article. Review.

2

Development of biosimilars in an era of oncologic drug shortages.

Li E, Subramanian J, Anderson S, Thomas D, McKinley J, Jacobs IA. Li E, et al. Drug Des Devel Ther. 2015 Jun 24;9:3247-55. doi: 10.2147/DDDT.S75219. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26150698 Free PMC article. Review.

3

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.

Subramanian J, Cavenagh J, Desai B, Jacobs I. Subramanian J, et al. Among authors: jacobs i. Cancer Manag Res. 2017 Apr 24;9:131-140. doi: 10.2147/CMAR.S120589. eCollection 2017. Cancer Manag Res. 2017. PMID: 28479860 Free PMC article. Review.

4

Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?

Nixon AB, Schalper KA, Jacobs I, Potluri S, Wang IM, Fleener C. Nixon AB, et al. Among authors: jacobs i. J Immunother Cancer. 2019 Nov 27;7(1):325. doi: 10.1186/s40425-019-0799-2. J Immunother Cancer. 2019. PMID: 31775882 Free PMC article. Review.

5

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.

Rosen LS, Jacobs IA, Burkes RL. Rosen LS, et al. Target Oncol. 2017 Oct;12(5):599-610. doi: 10.1007/s11523-017-0518-1. Target Oncol. 2017. PMID: 28801849 Free PMC article. Review.

6

Biosimilars: Extrapolation for oncology.

Curigliano G, O'Connor DP, Rosenberg JA, Jacobs I. Curigliano G, et al. Among authors: jacobs i. Crit Rev Oncol Hematol. 2016 Aug;104:131-7. doi: 10.1016/j.critrevonc.2016.06.002. Epub 2016 Jun 15. Crit Rev Oncol Hematol. 2016. PMID: 27354233 Free article. Review.

7

Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.

Anderson KC, Landgren O, Arend RC, Chou J, Jacobs IA. Anderson KC, et al. Future Oncol. 2019 Oct;15(28):3267-3281. doi: 10.2217/fon-2019-0368. Epub 2019 Aug 9. Future Oncol. 2019. PMID: 31394933 Free article. Review.

8

Biosimilars and cancer treatment of older patients.

Lichtman SM, Reske T, Jacobs IA. Lichtman SM, et al. J Geriatr Oncol. 2016 Mar;7(1 Suppl):S1-8. doi: 10.1016/j.jgo.2016.01.002. Epub 2016 Feb 5. J Geriatr Oncol. 2016. PMID: 26856525 Free article.

9

Biosimilars in oncology: from development to clinical practice.

Rak Tkaczuk KH, Jacobs IA. Rak Tkaczuk KH, et al. Semin Oncol. 2014 Apr;41 Suppl 3:S3-S12. doi: 10.1053/j.seminoncol.2014.03.008. Epub 2014 Mar 13. Semin Oncol. 2014. PMID: 24767633 Free article. Review.

10

The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.

Brown JR, Cymbalista F, Sharman J, Jacobs I, Nava-Parada P, Mato A. Brown JR, et al. Among authors: jacobs i. Oncologist. 2018 Mar;23(3):288-296. doi: 10.1634/theoncologist.2017-0150. Epub 2017 Dec 6. Oncologist. 2018. PMID: 29212732 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

936 results

Search Page